Bharat Biotech seeks nod for phase-3 clinical trials of nasal vaccine

The Hyderabad-based vaccine maker conducted phase 2 trials on 650 volunteers

Covaxin maker Bharat Biotech has sought approval to start phase-3 clinical trials for its intranasal Covid-19 vaccine candidate BBV154 from India’s drug regulator. The company plans to administer the nasal vaccine as a booster dose for those who have already received two shots of any Covid vaccine, sources revealed.

A company source said, “We have submitted a phase 3 clinical trial application to DCGI. An intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns. Intranasal vaccines have the potential to prevent transmission.”

Details about the size of the phase 3 clinical trial are not